Korea Celltrion Healthcare, the marketing arm of the biopharmaceutical company Celltrion won a huge deal in France last Friday (2nd November 2018) with big tenders for Herzuma, a biosimilar of Roche’s blockbuster breast cancer treatment Herceptin. Herzuma, with indications for positive metastatic breast cancer, early cancer, and metastatic gastric cancer…
France Thierry Philip, president of Institut Curie, talks about the organization, the effect of cancer on Social Security and the need for a cohesive European plan involving all oncology research institutions and policy-makers. The most important achievement was the accreditation as a comprehensive cancer centre by the OECI One of…
Malaysia Dr. Saunthari Somasundaram walks us through the NCSM’s mission to raise awareness on cancer prevention and early diagnosis in Malaysia. She details the need for more government support to make cancer education a pillar in healthcare and discredits the idea that care only includes treatment and cure. Could you…
Algeria Professor Kamel Bouzid, president of the Algerian Society of Medical Oncology, provides an insight into the efforts to fight against cancer in Algeria. Could you please give us an overview of the cancer prevalence in Algeria? In Algeria, 75 percent of cancers are metastasized cancers, and only 25 percent are…
Cancer Turkey has one of the most revered Social Security Systems in the world, providing its citizens with free healthcare and access to a long list of innovative cancer drugs. However, with one of the youngest populations in Europe, the sustainability of the system is uncertain as its incredibly young population gets older…
Cancer Novartis receives NHS approval for their CAR T-cell therapy to treat leukaemia in children, 10 days after receiving European Commission (EC) approval. “It’s fantastic news for children and young people with this form of leukaemia.” Prof Charles Swanton, Cancer Research UK’s Dubbed as the future of cancer therapy, Kymriah, Novartis’ gene-modifying treatment…
Spain Josep Taberno MD PhD, director of VHIO, introduces the important work being conducted by the cancer institute in Spain as well as emerging trends in oncology. Can you tell us about VHIO? “ The complexities in cancer treatment and care are myriad. That said, I firmly believe that we can…
Turkey Mahmut Gümüş, president of the Turkish Society of Medical Oncology, paints a descriptive picture of the oncology situation in the country, with the looming epidemiological shift set to transform the healthcare sector. However, he has high hopes that the country will continue to prioritize oncology as a key therapeutic area…
China This week, China has fast-tracked approval for 48 “much-needed medicines.” Regulators gave special consideration to new treatments for rare diseases as well as drugs that target serious, life-threatening illnesses, like cancer. Authorities were made to sit up and listen following the box office success of a low budget film called “Dying to…
Switzerland In an exclusive interview, Bruno Strigini, global CEO of Novartis Oncology, discusses the logic of the company’s separate oncology business unit, the significance of US FDA approval for the new CAR-T cell therapy, Kymriah, and the issues around pricing for this revolutionary treatment. * Please note that this interview was…
Poland Beata Ambroziewicz, board member of the Polish cancer patient coalition, an umbrella organization that encompasses 41 Polish cancer organizations, discusses the challenges and possible solutions in regard to hospital care and market access in the oncology community. She also highlights the importance of a coordinated approach towards the treatment of…
Austria Mario Huber, general manager of PharmaMar Austria, a multinational and an innovative oncology-based Spanish company, discusses the growth of the company in Austria and the reasons behind the success of Yondelis®, the company’s flagship product. Furthermore, he provides an overview of the clinical trials the Austrian affiliate is undertaking and…
See our Cookie Privacy Policy Here